Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06930976 · ClinicalTrials.gov registry record · NA

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells

A NA study of Metabolism and Glucose, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT06930976: Recruiting NA study of Metabolism and Glucose, sponsored by Vanderbilt University Medical Center.

NCT06930976 is a NA study of Metabolism and Glucose that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 12 participants, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06930976, a NA study of Metabolism and Glucose, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.

Primary Outcome

Detection of 13C6-glucose-derived metabolites in neutrophils, monocytes, CD4 T cells, and CD8 T cells using gas and liquid chromatography-mass spectrometry (GC-MS and LC-MS) following magnetic enrichment of these immune cell subsets.

Interventions

  • DRUG 13C6-Glucose

Study Locations (1)

Tennessee

  • Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2025-10-01
Est. Completion 2027-06-30
Phase NA

What NCT06930976 shows while recruiting

NCT06930976 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 13,265-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower).

The record links to 4 conditions, with Metabolism appearing as the primary indexed condition, and to 1 intervention - of which 13C6-Glucose is the first listed.

NCT06930976 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT06930976 about?

NCT06930976 is a clinical study titled "Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells". The purpose of this study is to understand how cells of the immune system use the common sugar glucose to fuel energy production and as a building block within the cell. Investigators will intravenously infuse a non-radioactive glucose tracer into participants over a few hours and collect immune cel...

What is the current status of trial NCT06930976?

This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2025-10-01. Estimated completion is 2027-06-30.

What conditions does trial NCT06930976 study?

This clinical trial studies the following conditions: Metabolism, Glucose, Immune System and Related Disorders, Isotope Labeling.

What interventions are being tested in trial NCT06930976?

The interventions under investigation include: 13C6-Glucose (DRUG).

Who is sponsoring clinical trial NCT06930976?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06930976 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metabolism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06930976's enrollment target sits among peer trials

12 15th of 19 higher than 5 of 19 other Metabolism trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metabolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06930976, the US trial registry maintained by the National Library of Medicine. NCT06930976 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.